



For HER2+ metastatic
breast cancer (mBC)

**Margenza**[®]
(margetuximab-cmkb)
250 mg/10 mL injection for intravenous use



*“What’s next
in the journey to
strengthen my fight?”*



HER2+=human epidermal growth factor receptor 2 positive.

Actor portrayals.

What does MARGENZA treat?

MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

SELECT SAFETY INFORMATION

What is the most important information I should know about MARGENZA?

MARGENZA can cause serious side effects, including:

- **Heart problems that may affect your heart’s ability to pump blood.** Your doctor will run tests to monitor your heart function before and during treatment with MARGENZA. Based on test results, your doctor may hold or discontinue treatment with MARGENZA.
- **Harm to your unborn baby.** Exposure to MARGENZA during pregnancy or within 4 months prior to conception can result in the death of an unborn baby or birth defects. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with MARGENZA.

Please see additional Important Safety Information throughout and accompanying [Full Prescribing Information](#), including **BOXED WARNING**.

“What’s next in my journey?”

Throughout your journey with HER2+ mBC, you’ve likely faced many difficult decisions. At this point, strengthening your fight may mean considering what’s next.

If you’ve decided to explore additional options, MARGENZA may be able to help in the next phase of your treatment.

What’s next could help you continue the fight.

MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Enclosed you will find information about MARGENZA.




Actor portrayals.

Margenza[®]
(margetuximab-cmkb)
250 mg/10 mL injection for intravenous use

Designed to work differently

MARGENZA is the first and only FDA-approved treatment for HER2+ mBC that's been engineered to help improve your body's immune response.* That means it's built to help improve how your body fights your cancer.

*This is how it was shown to work in laboratory studies. Clinical significance is unknown.



Fight by blocking

MARGENZA targets the human epidermal growth factor receptor 2 (HER2) protein to help stop the chemical signals that tell the cancer cells to grow, divide, and survive.

Engineered section of MARGENZA

Fight by activating

MARGENZA was engineered to improve how your body's immune system fights the cancer, attracting more immune cells to the tumor and enabling stronger immune cell activation to destroy the cancer cells.

FDA=US Food and Drug Administration.

Watch video:

Scan to see **MARGENZA**
in action.



Actor portrayals.

SELECT SAFETY INFORMATION

MARGENZA can cause serious side effects, including:

- **Heart problems that may affect your heart's ability to pump blood.** Your doctor will run tests to monitor your heart function before and during treatment with MARGENZA. Based on test results, your doctor may hold or discontinue treatment with MARGENZA.
 - Tell your healthcare provider right away if you get any of the following signs and symptoms: new or worsening shortness of breath, coughing, feeling tired, swelling of the ankles or legs, swelling of the face, irregular heartbeat or palpitations, sudden weight gain of more than 5 pounds in 24 hours, dizziness, light-headedness, or loss of consciousness.

Please see additional Important Safety Information throughout and accompanying [Full Prescribing Information](#), including **BOXED WARNING**.

Margenza[®]
(margetuximab-cmkb)
250 mg/10 mL injection for intravenous use



Actor portrayal.

Please see additional Important Safety Information throughout and accompanying [Full Prescribing Information](#), including **BOXED WARNING**.

Proven to delay cancer progression

In a clinical trial of 536 patients, people treated with MARGENZA plus chemotherapy lived longer without the cancer growing or spreading than people who were treated with trastuzumab plus chemotherapy.



24% lower risk of disease progression or death with MARGENZA plus chemotherapy vs trastuzumab plus chemotherapy

Median* time without cancer growing or spreading

5.8 months

MARGENZA plus chemotherapy (266 people)

4.9 months

Trastuzumab plus chemotherapy (270 people)

*Median is the middle number in a group of numbers that are listed from lowest to highest.

†Statistical significance describes a mathematical measure of difference between groups. The difference is statistically significant if it is greater than what might be expected to happen by chance alone.

There was not a statistically significant[†] difference in how long patients lived when comparing MARGENZA plus chemotherapy and trastuzumab plus chemotherapy.

Patients enrolled in the study had metastasis in the bone, lymph node, lung, liver, breast, skin, or brain. The median age of participants in the study was 56 years (age range 27-86 years), and 78% of patients were less than 65 years old.

SELECT SAFETY INFORMATION

MARGENZA can cause serious side effects, including:

- **Harm to your unborn baby.** Exposure to MARGENZA during pregnancy or within 4 months prior to conception can result in the death of an unborn baby or birth defects. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with MARGENZA.
 - If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with MARGENZA.
 - Birth control should be used while receiving MARGENZA and for 4 months after your last dose of MARGENZA.

Well-characterized safety profile

The clinical trial where MARGENZA plus chemotherapy and trastuzumab plus chemotherapy were studied showed they both had similar side effects.

Serious side effects:



Heart problems that may affect your heart's ability to pump blood

Harm to your unborn baby



Infusion-related reactions (IRRs)

Possible symptoms of IRRs include fever, chills, joint pain, cough, dizziness, tiredness, nausea, vomiting, headache, sweating, fast heart rate, low blood pressure, itching, rash, hives, and shortness of breath. Your doctor will monitor you for IRRs.

The most common side effects experienced by patients who received MARGENZA in combination with chemotherapy:

- Fatigue/weakness
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Headache
- Fever
- Hair loss
- Abdominal pain
- Peripheral neuropathy (weakness, numbness, pain, and/or tingling in hands and feet)
- Joint and muscle pain
- Cough
- Decreased appetite
- Shortness of breath
- Infusion-related reactions
- Redness/swelling and pain on the palms of the hands and soles of the feet (hand-foot syndrome)
- Pain in arms and legs

Margenza[®]
(margetuximab-cmkb)
250 mg/10 mL injection for intravenous use

Reminder:

Be sure to contact your healthcare team right away if you have questions or are worried about any side effects.

Please see additional Important Safety Information throughout and accompanying [Full Prescribing Information](#), including **BOXED WARNING**.

Actor portrayal.



Margenza[®]
(margetuximab-cmkb)
250 mg/10 mL injection for intravenous use

Did you know?

The National Comprehensive Cancer Network[®] (NCCN[®]), a respected group of cancer centers in the United States, recommends margetuximab-cmkb (MARGENZA) + chemotherapy* as a systemic therapy option for HER2+ mBC in 4th line and beyond in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]).

*Capecitabine, eribulin, gemcitabine, or vinorelbine.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Breast Cancer V.5.2025. ©National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 16, 2025. To view the most recent and complete version of the guideline, go online to [NCCN.org](https://www.nccn.org). NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Please see additional Important Safety Information throughout and accompanying [Full Prescribing Information](#), including **BOXED WARNING**.

Actor portrayals.

Pairs with the chemo that works best for you


Your doctor has the flexibility to consider various chemotherapy options that you tolerate best based on your individual needs, past treatments, and experiences.

In the clinical trial where MARGENZA was studied, four different chemotherapies were used:

✓ **Capecitabine** ✓ **Eribulin** ✓ **Gemcitabine** ✓ **Vinorelbine**

What to expect with MARGENZA

DOSE



INITIAL INFUSION



SUBSEQUENT INFUSION



On days when both MARGENZA and chemotherapy are to be administered, MARGENZA may be administered immediately after chemotherapy completion.

SELECT SAFETY INFORMATION

What are other possible serious side effects of MARGENZA?

Infusion-related reactions. MARGENZA is a medicine that is delivered into a vein through a needle as an infusion. MARGENZA has been associated with infusion-related reactions which can include fever, chills, joint pain, cough, dizziness, tiredness, nausea, vomiting, headache, sweating, fast heart rate, low blood pressure, itching, rash, hives, and shortness of breath. Your healthcare team will monitor you during treatment with MARGENZA and may slow or stop your infusion if you have side effects. You may need to permanently stop MARGENZA if you have a severe infusion reaction.

Access to treatment and support

As you navigate your treatment and all that is going on during this time, support is more important than ever—both personal and financial. That's why TerSera SupportSource is here to help make sure you're getting the financial access you need for MARGENZA.



TerSera SupportSource helps you understand what financial support may be available.

MARGENZA Co-pay Savings Program

Eligible patients may reduce out-of-pocket MARGENZA prescription costs with easy-to-initiate co-pay enrollment.*

MARGENZA Patient Assistance Program

Eligible uninsured or underinsured patients may receive MARGENZA at no cost through the Patient Assistance Program. Terms and conditions apply.


Contact us:



Scan to learn more about **TerSera SupportSource for MARGENZA**, or call **1-833-377-HER2 (4372)**.

*For eligible patients, the co-pay card is subject to an annual limit. You are not eligible if prescriptions are paid for by any state or other federally funded programs. Additional terms and conditions apply.

Support groups like the ones listed below may help by providing insight, advice, and community. By being listed here, the organizations do not specifically endorse MARGENZA.



LBBC.org



Actor portrayals.

What does MARGENZA treat?

MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Important Safety Information

What is the most important information I should know about MARGENZA?

MARGENZA can cause serious side effects, including:

- **Heart problems that may affect your heart's ability to pump blood.** Your doctor will run tests to monitor your heart function before and during treatment with MARGENZA. Based on test results, your doctor may hold or discontinue treatment with MARGENZA.
 - Tell your healthcare provider right away if you get any of the following signs and symptoms: new or worsening shortness of breath, coughing, feeling tired, swelling of the ankles or legs, swelling of the face, irregular heartbeat or palpitations, sudden weight gain of more than 5 pounds in 24 hours, dizziness, lightheadedness, or loss of consciousness.
- **Harm to your unborn baby.** Exposure to MARGENZA during pregnancy or within 4 months prior to conception can result in the death of an unborn baby or birth defects. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with MARGENZA.

- If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with MARGENZA.
- Birth control should be used while receiving MARGENZA and for 4 months after your last dose of MARGENZA.

What are other possible serious side effects of MARGENZA?

Infusion-related reactions. MARGENZA is a medicine that is delivered into a vein through a needle as an infusion. MARGENZA has been associated with infusion-related reactions which can include fever, chills, joint pain, cough, dizziness, tiredness, nausea, vomiting, headache, sweating, fast heart rate, low blood pressure, itching, rash, hives, and shortness of breath. Your healthcare team will monitor you during treatment with MARGENZA and may slow or stop your infusion if you have side effects. You may need to permanently stop MARGENZA if you have a severe infusion reaction.

Before you receive MARGENZA, tell your doctor if you are breastfeeding. It is not known if MARGENZA could pass into breast milk and harm your baby.


What are the most common side effects of MARGENZA in combination with chemotherapy?

The most common side effects with MARGENZA in combination with chemotherapy are:

- Fatigue/weakness
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Headache
- Fever
- Hair loss
- Abdominal pain
- Peripheral neuropathy (weakness, numbness, pain, and/or tingling in hands and feet)
- Joint and muscle pain
- Cough
- Decreased appetite
- Difficulty breathing
- Infusion-related reactions
- Redness/swelling and pain on the palms of the hands and soles of the feet (hand-foot syndrome)
- Pain in arms and legs

These are not all the possible side effects of MARGENZA. Your doctor may stop treatment if serious side effects happen. Be sure to contact your healthcare team right away if you have questions or are worried about any side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch. You may also contact TerSera Therapeutics at 1-844-334-4035 or medicalinformation@tersera.com.



Actor portrayals.

Please see accompanying [Full Prescribing Information](#), including BOXED WARNING.

“What’s next in my journey, now?”

To learn more about MARGENZA,
visit [MARGENZA.com](https://www.margenza.com)



Talk to your doctor about MARGENZA today.

What does MARGENZA treat?

MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

SELECT SAFETY INFORMATION

What is the most important information I should know about MARGENZA?

MARGENZA can cause serious side effects, including:

- **Heart problems that may affect your heart’s ability to pump blood.** Your doctor will run tests to monitor your heart function before and during treatment with MARGENZA. Based on test results, your doctor may hold or discontinue treatment with MARGENZA.
 - Tell your healthcare provider right away if you get any of the following signs and symptoms: new or worsening shortness of breath, coughing, feeling tired, swelling of the ankles or legs, swelling of the face, irregular heartbeat or palpitations, sudden weight gain of more than 5 pounds in 24 hours, dizziness, light-headedness, or loss of consciousness.
- **Harm to your unborn baby.** Exposure to MARGENZA during pregnancy or within 4 months prior to conception can result in the death of an unborn baby or birth defects. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with MARGENZA.
 - If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with MARGENZA.
 - Birth control should be used while receiving MARGENZA and for 4 months after your last dose of MARGENZA.

Please see additional Important Safety Information throughout and accompanying [Full Prescribing Information](#), including BOXED WARNING.



MARGENZA, TERSERA, and the TERSERA logo are registered trademarks of TerSera Therapeutics LLC. All other trademarks are the property of their respective owners.
©2026 TerSera Therapeutics LLC. All rights reserved. MAR-P-0363 (01/2026)

